Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: CRSP

CRISPR Therapeutics AG

Healthcare | Biotechnology

No licensed closing price on file for CRSP. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-4.71

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 02:39 UTC.

What CRISPR Therapeutics AG does

The company is a biopharmaceutical firm focused on developing CRISPR-based gene-editing therapies for serious diseases. Its most advanced program, CASGEVY, became the first approved CRISPR therapy worldwide and treats severe sickle cell disease and transfusion-dependent beta thalassemia using edited cells. The company maintains a pipeline across four therapeutic areas: hemoglobinopathies, in vivo liver editing, CAR T cell therapies, and regenerative medicine for Type 1 diabetes.

Summarized from CRISPR Therapeutics AG’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-4.71
Debt/equity0.34

Revenue, margins & earnings

FY2021 Revenue: $915M — margin split not shown (non-operating gains)$915MFY2021FY2022: net loss $650M on revenue $1M$1MFY2022FY2023: net loss $154M on revenue $371M$371MFY2023FY2024: net loss $366M on revenue $37M$37MFY2024FY2025: net loss $582M on revenue $4M$4MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-16
  • 2026-10-16DirectorStock Option (Right to Buy)Option exercise-30,000—
  • 2026-10-16DirectorSale-14,514$720.4K
  • 2026-10-16DirectorOption exercise30,000$420.0K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does CRISPR Therapeutics AG do?

The company is a biopharmaceutical firm focused on developing CRISPR-based gene-editing therapies for serious diseases.

When did CRSP last file with the SEC?

CRISPR Therapeutics AG's most recent SEC filing on record is a 8-K filed 2026-06-04. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 02:39 UTC. This page is also available as JSON at /api/data?ticker=CRSP and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CRSP and 5,000+ tickers.

Create a free account — keep CRSP
For your agent
GET /api/data?ticker=CRSP

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt